Related Experiment Video
Updated: Sep 22, 2026
Experimental Human Pneumococcal Carriage
Published on: February 15, 2013
Improving Pneumococcus Vaccination Rates Among Patients With Cancer: An ASCO/CDC/CMSS-Sponsored Quality Improvement
Lisa Law1, Andria Albert2, Janise Roh3
1Department of Hematology Oncology, Kaiser Permanente, Roseville, CA, USA.
Background:
Invasive pneumococcal disease poses a substantial danger to patients with cancer, who experience higher rates of infection, antimicrobial resistance, morbidity, and mortality. Pneumococcal vaccination reduces both cases of pneumonia and hospitalizations in this population. The Advisory Committee on Immunization Practices, National Comprehensive Cancer Network, and American Society of Clinical Oncology recommend vaccination for immunocompromised adults, including those with newly diagnosed cancer prior to chemotherapy.
Methods:
As part of the Specialty Societies Advancing Adult Immunization quality improvement initiative, the Kaiser Permanente oncology practice evaluated and improved pneumococcal vaccination rates among patients receiving chemotherapy. Baseline rates were established through workflow review. Three sequential plan-do-study-act cycles were implemented over 3 months targeting a 10% improvement. Interventions included implementing workflow optimization, staff education, and having on-site administration.
Results:
Vaccination rates increased from 29.5% to 32.8% over 5 months, exceeding the national average of 23% for high-risk adults aged 19 to 64 years. Education for health care practitioners, reminders, and on-site vaccine availability were most effective. The greatest improvement occurred during plan-do-study-act cycle 3 with in-clinic vaccination. No adverse reactions were observed.
Conclusion:
An on-site, team-based vaccination model improved pneumococcal immunization rates. Integrating vaccination into oncology workflows can enhance guideline adherence and protect immunocompromised patients.
More Related Videos
09:20Investigating the Effects of Probiotics on Pneumococcal Colonization Using an In Vitro Adherence Assay
Published on: April 28, 2014
11:32Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Related Concept Videos
01:22Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:30Pneumonia III: Complications and Assessment
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.